Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium

Bruinsma, 2016, Active surveillance for prostate cancer: a narrative review of clinical guidelines, Nat Rev Urol, 13, 151, 10.1038/nrurol.2015.313 Lam, 2019, EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE study), Eur Urol, 76, 790, 10.1016/j.eururo.2019.09.020 Ouzzane, 2015, Magnetic resonance imaging targeted biopsy improves selection of patients considered for active surveillance for clinically low risk prostate cancer based on systematic biopsies, J Urol, 194, 350, 10.1016/j.juro.2015.02.2938 Klotz, 2020, Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up, Eur Urol, 77, 311, 10.1016/j.eururo.2019.10.007 Mottet, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, 79, 243, 10.1016/j.eururo.2020.09.042 Bruinsma, 2018, The Movember Foundation’s GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date, BJU Int, 121, 737, 10.1111/bju.14106 Schoots, 2018, MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?, Transl Androl Urol, 7, 70, 10.21037/tau.2017.12.31 Bruinsma, 2017, Expert consensus document: Semantics in active surveillance for men with localized prostate cancer—results of a modified Delphi consensus procedure, Nat Rev Urol, 14, 312, 10.1038/nrurol.2017.26 Klein, 2003 Mamawala, 2020, Utility of multiparametric magnetic resonance imaging in the risk stratification of men with grade group 1 prostate cancer on active surveillance, BJU Int, 125, 861, 10.1111/bju.15033 Stavrinides, 2020, Five-year outcomes of magnetic resonance imaging-based active surveillance for prostate cancer: a large cohort study, Eur Urol, 78, 443, 10.1016/j.eururo.2020.03.035 Gallagher, 2019, Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies, BJU Int, 123, 429, 10.1111/bju.14513 Deniffel, 2020, Does the visibility of grade group 1 prostate cancer on baseline multiparametric magnetic resonance imaging impact clinical outcomes?, J Urol, 204, 1187, 10.1097/JU.0000000000001157 Hsiang, 2021, Outcomes of serial multiparametric magnetic resonance imaging and subsequent biopsy in men with low-risk prostate cancer managed with active surveillance, Eur Urol Focus, 7, 47, 10.1016/j.euf.2019.05.011 Chu CE, Cowan JE, Lonergan PE, et␣al. Diagnostic accuracy and prognostic value of serial prostate multiparametric magnetic resonance imaging in men on active surveillance for prostate cancer. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2020.11.007 Olivier, 2019, Low-risk prostate cancer selected for active surveillance with negative MRI at entry: can repeat biopsies at 1 year be avoided? A pilot study, World J Urol, 37, 253, 10.1007/s00345-018-2420-6 Thurtle, 2018, Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer, BJU Int, 122, 59, 10.1111/bju.14166 Van Hemelrijck, 2019, Reasons for discontinuing active surveillance: assessment of 21 centres in 12 countries in the Movember GAP3 Consortium, Eur Urol, 75, 523, 10.1016/j.eururo.2018.10.025 Inoue, 2014, Modeling grade progression in an active surveillance study, Stat Med, 33, 930, 10.1002/sim.6003 Kalapara, 2020, Adherence to active surveillance protocols for low-risk prostate cancer: results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance initiative, Eur Urol Oncol, 3, 80, 10.1016/j.euo.2019.08.014